Lilly reported an extension of TRIUMPH-1 for 532 participants who had a baseline BMI of at least 35 and completed and tolerated treatment in the main study. Follow-up extended to 104 weeks.
An extension with selected participants
Extension findings describe this selected group. The design also allowed changes to treatment, including moving the original placebo group to retatrutide, so the later estimates address a different question from the main placebo-controlled comparison.
How to interpret the evidence
Check who entered the extension and what happened to the original comparator before using its figures in a study summary.
When comparing results, record the primary outcome, the measurement week, and whether the analysis included outcomes after treatment stopped.